

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**July 2, 2024**

---

**I New Study ReReview**

**NRG-GY034**, A Randomized Phase 1/2 Trial Evaluating The Addition Of ASTX660 (Tolinapant) To Weekly Paclitaxel With Or Without Bevacizumab In Patients With Recurrent Platinum Resistant And Platinum Refractory Epithelial Ovarian Cancer (Version Date 06/06/24)

---

**II Continuing Review**

**10366**, A Phase 1/Randomized Phase 2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma (Version Date 01/12/24)

---

**III Continuing Review**

**NRG-LU004**, Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1) (Version Date 05/28/24)

---

**IV Continuing Review**

**10592**, A Randomized Phase 2 Study of ATR inhibition in advanced PD-(L)1-refractory Merkel cell carcinoma: The MATRiX Trial (Version Date 04/16/24)

---